Isolated limb infusion with melphalan and actinomycin D for melanoma: A systematic review

Journal of Surgical Oncology

Volumn 109, Issue 4, 2014, Pages 348-351

  Kroon, Hidde M ^a   Huismans, Anna M ^a   Kam, Peter C A ^b,c,d   Thompson, John F ^a,c,d  

^a MELANOMA INSTITUTE AUSTRALIA   (Australia)

^b UNIVERSITY OF SYDNEY   (Australia)

^c UNIVERSITY OF SYDNEY   (Australia)

^d ROYAL PRINCE ALFRED HOSPITAL   (Australia)

Author keywords

actinomycin D; isolated limb perfusion; melanoma; melphalan

Indexed keywords

ACTINOMYCIN D; ISOLATED LIMB PERFUSION; MELANOMA; MELPHALAN;

ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, ALKYLATING; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; DACTINOMYCIN; HUMANS; MELANOMA; MELPHALAN; NEOPLASM METASTASIS;

EID: 84893985126     PISSN: 00224790     EISSN: 10969098     Source Type: Journal    
DOI: 10.1002/jso.23553     Document Type: Review

References (39)

1. Balch CM, Gershenwald JE, Soong SJ, et al.: Update on the melanoma staging system: The importance of sentinel node staging and primary tumor mitotic rate. J Surg Oncol 2011; 104: 379-385.
2. Hodi FS, O'Day SJ, McDermott DF, et al.: Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
3. Flaherty KT, Puzanov I, Kim KB, et al.: Inhibition of mutated, activated BRAF in metastatic melanoma. N Engl J Med 2010; 363: 809-819.
4. Hoekstra HJ:, The European approach to in-transit melanoma lesions. Int J Hyperthermia 2008; 26: 227-237.
5. Thompson JF, De Wilt JHW:, Isolated limb perfusion in the management of patients with recurrent limb melanoma: An important but limited role. Ann Surg Oncol 2001; 8: 564-565.
6. Noorda EM, Vrouenraets BC, Nieweg OE, et al.: Safety and efficacy of isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9: 968-974.
7. van Etten B, van Geel AN, de Wilt JH, et al.: Fifty tumor necrosis factor-based isolated limb perfusions for limb salvage in patients older than 75 years with limb-threatening soft tissue sarcomas and other extremity tumors. Ann Surg Oncol 2003; 10: 32-37.
8. McMasters KM:, Isolated limb perfusion in elderly melanoma patients. Ann Surg Oncol 2002; 9: 939-940.
9. Thompson JF, Waugh RC, Saw RPM, et al.: Isolated limb infusion with melphalan for recurrent limb melanoma: A simple alternative to isolated limb perfusion. Reg Cancer Treat 1994; 7: 188-192.
10. Brady MS, Brown K, Patel A, et al.: A phase II trial of isolated limb infusion with melphalan and dactinomycin for regional melanoma and soft tissue sarcoma of the extremity. Ann Surg Oncol 2006; 13: 1123-1129.
11. Beasley GM, Petersen RP, Yoo J, et al.: Isolated limb infusion for in-transit malignant melanoma of the extremity: A well tolerated but less effective alternative to hyperthermic isolated limb perfusion. Ann Surg Oncol 2008; 15: 2195-2205.
12. Mian R, Henderson MA, Speakman D, et al.: Isolated limb infusion for melanoma: A simple alternative to isolated limb perfusion. Can J Surg 2001; 44: 189-192.
13. Marsden J, Samarasinghe V, Duddy M, et al.: Regional chemotherapy for inoperable limb cancer using isolated limb infusion. Br J Dermatol 2008; 159: 10.
14. Kroon HM, Thompson JF:, Isolated limb infusion: A review. J Surg Oncol 2009; 100: 169-177.
15. Kroon HM, Huismans AM, Waugh RC, et al.: Isolated limb infusion: Technical aspects. J Surg Oncol In press
16. Leeflang MM, Deeks JJ, Gatsonis C, et al.: Systematic reviews of diagnostic test accuracy. Ann Intern Med 2008; 149: 889-897.
17. Barker FG II, Carter BS:, Synthesizing medical evidence: Systematic reviews and metaanalyses. Neurosurg Focus 2005; 19: E5.
18. Raymond AK, Beasley GM, Broadwater G, et al.: Current trends in regional therapy for melanoma: Lessons learned from 225 regional chemotherapy treatments between 1995 and 2010 at a single institution. J Am Coll Surg 2011; 213: 306-316.
19. Beasley GM, Caudle A, Petersen RP, et al.: A multi-institutional experience of isolated limb infusion: Defining response and toxicity in the US. J Am Coll Surg 2009; 208: 706-715.
20. Kroon HM, Moncrieff M, Kam PC, et al.: Outcomes following isolated limb infusion. A 14-year experience. Ann Surg Oncol 2008; 15: 3003-3013.
21. Lindner P, Doubrovsky A, Kam PCA, et al.: Prognostic factors after isolated limb infusion with cytotoxic agents for melanoma. Ann Surg Oncol 2002; 9: 127-136.
22. Duprat Neto JP, Mauro AC, Molina AS, et al.: Isolated limb infusion with hyperthermia and chemotherapy for advanced limb malignancy: Factors influencing toxicity. ANZ J Surg 2012; Epub ahead of print.
23. Wong J, Chen YA, Fisher KJ, et al.: Isolated limb infusion in a series of over 100 infusions: A single-center experience. Ann Surg Oncol 2013; 20: 1121-1127.
24. Coventry BJ, Kroon HM, Giles MH, et al.: Australian multi-center study of isolated limb infusion chemotherapy for melanoma: Experience outside of the Sydney Melanoma Unit. J Surg Oncol (under review).
25. Wieberdink J, Benckhuijsen C, Braat RP, et al.: Dosimetry in isolated perfusion of the limbs by assessment of perfused tissue and grading of toxic reactions. Eur J Cancer Clin Oncol 1982; 18: 905-910.
26. World Health Organization: WHO handbook for reporting results of cancer treatments (WHO offset publication no. 48). Geneva, Switzerland: World Health Organization; 1979.
27. Kroon HM, Moncrieff M, Kam PC, et al.: Factors predictive of acute regional toxicity after isolated limb infusion with melphalan and actinomycin-D in melanoma patients. Ann Surg Oncol 2009; 16: 1184-1192.
28. Scott RN, Blackie R, Kerr DJ, et al.: Melphalan in isolated limb perfusion for malignant melanoma, bolus or divided dose, tissue levels, the pH effect. In:, Jakesz R, Rainer H, editors. Progress in regional cancer therapy. Berlin-Heidelberg, NY: Springer-Verlag; 1990; pp. 195-200.
29. Klaase JM, Kroon BBR, Beijnen JH, et al.: Melphalan tissue concentrations in patients treated with regional isolated perfusion for melanoma of the lower limb. Br J Cancer 1994; 70: 151-153.
30. McMahon N, Cheng TY, Beasley GM, et al.: Optimizing melphalan pharmacokinetics in regional melanoma therapy: Does correcting for ideal body weight alter regional response or toxicity ? Ann Surg Oncol 2009; 16: 953-961.
31. Huismans AM, Kroon HM, Haydu LE, et al.: Correcting melphalan dose for ideal body weight in isolated limb infusion, does it influence toxicity or response ? Ann Surg Oncol 2012; 19: 3050-3056.
32. Huismans AM, Kroon HM, Kam PCA, et al.: Does increased experience with isolated limb infusion for advanced melanoma influence outcome? A comparison of two treatment periods at a single institution. Ann Surg Oncol 2011; 18: 1877-1883.
33. Creech O Jr, Krementz ET, Ryan RF:, Chemotherapy of melanoma of the extremities by isolated perfusion. Cancer Chemother Rep 1962; 16: 579-581.
34. Schraffordt Koops H, Lejeune FJ, Kroon BBR, et al.: Isolated limb perfusion for melanoma: Technical aspects. In:, Thompson JF, Morton DL, Kroon BBR, editors. Textbook of melanoma. London, UK: Martin Dunitz; 2004; pp. 404-409.
35. Testori A, Verhoef C, Kroon HM, et al.: Treatment of melanoma metastases in a limb by isolated limb perfusion and isolated limb infusion. J Surg Oncol 2011; 104: 397-404.
36. Kroon HM, Lin DY, Kam PC, et al.: Safety and efficacy of isolated limb infusion with cytotoxic drugs in elderly patients with advanced locoregional melanoma. Ann Surg 2009; 246: 1008-1013.
37. Kroon HM, Lin DY, Kam PC, et al.: Isolated limb infusion as palliative treatment for advanced limb disease in patients with AJCC stage IV melanoma. Ann Surg Oncol 2009; 16: 1193-1201.
38. Beasley GM, McMahon N, Sanders G, et al.: A phase 1 study of systemic ADH-1 in combination with melphalan via isolated limb infusion in patients with locally advanced in-transit malignant melanoma. Cancer 2009; 115: 4766-4774.
39. Beasley GM, Coleman AP, Raymond A, et al.: A phase I multi-institutional study of systemic sorafenib in conjunction with regional melphalan for in-transit melanoma of the extremity. Ann Surg Oncol 2012; 19: 3896-3905.